Drug-induced hypo- and hyperprolactinemia: Mechanisms, clinical and therapeutic consequences

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 8, 2013, Pages 955-968

  Voicu, Victor ^a   Medvedovici, Andrei ^b   Ranetti, Aurelian Emil ^c   Rǎdulescu, Flavian Ştefan ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF BUCHAREST   (Romania)

^c Central Military Hospital Bucharest   (Romania)

Author keywords

Anterior hypophysis; Antidepressants; Antipsychotics; Blood brain barrier; Dopamine D2 receptors; Hyperprolactinemia; LogBB; Therapeutic switching

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; ATROPINE; BROMOCRIPTINE; CABERGOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; NALOXONE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; PALIPERIDONE; PERGOLIDE; PHENOTHIAZINE; PROKINETIC AGENT; PROLACTIN; PROLACTIN RECEPTOR; RISPERIDONE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; THIOXANTHENE DERIVATIVE; UNINDEXED DRUG; VERAPAMIL; XENOBIOTIC AGENT;

BLOOD BRAIN BARRIER; DISORDERS OF HORMONE METABOLISM; DOSE RESPONSE; HUMAN; HYPERPROLACTINEMIA; HYPOPROLACTINEMIA; MENTAL STRESS; NEUROTRANSMISSION; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PROLACTIN RELEASE; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION;

ANTIPSYCHOTIC AGENTS; BLOOD-BRAIN BARRIER; HUMANS; HYPERPROLACTINEMIA; ISOXAZOLES; PIPERAZINES; PROLACTIN; PYRIMIDINES; QUINOLONES; RECEPTORS, DOPAMINE D2; RISPERIDONE; STRESS, PSYCHOLOGICAL; SULPIRIDE; XENOBIOTICS;

EID: 84880383383     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.791283     Document Type: Review

References (108)

1. Holt RI. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol 2008;22:28-37
2. Goffin V, Binart N, Touraine P, et al. Prolactin: The new biology of an old hormone. Annu Rev Physiol 2002;64:47-67
3. Sinha YN. Structural variants of prolactin: Occurrence and physiological significance. Endocr Rev 1995;16(3):354-69
4. Bernichtein S, Touraine P, Goffin V. New concepts in prolactin biology. J Endocrinol 2010;206:1-11
5. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: Structure, function, and regulation of secretion. Physiol Rev 2000;80:1523-631
6. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22:724-63
7. Ben-Jonathan N, LaPensee CR. Prolactin and its neuroendocrine control. In: Larry RS, editors. Encyclopedia of Neuroscience. Academic Press, Oxford; 2009. 1125-31
8. Clementi G, Nicoletti F, Patacchioli F, et al. Hypoprolactinemic action of calcitonin and the tuberoinfundibular dopaminergic system. J Neurochem 1983;40:885-6
9. Kanyicska B, Lerant A, Freeman ME. Endothelin is an autocrine regulator of prolactin secretion. Endocrinology 1998;139:5164-73
10. Apud JA, Cocchi D, Locatelli V, et al. Biochemical and functional aspects on the control of prolactin release by the hypothalamo-pituitary GABAergic system. Psychoneuroendocrinology 1989;14:3-17
11. Mukherjee A, Snyder G, McCann SM. Characterization of muscarinic cholinergic receptors on intact rat anterior pituitary cells. Life Sci 1980;27:475-82
12. Carmeliet P, Denef C. Immunocytochemical and pharmacological evidence for an intrinsic cholinomimetic system modulating prolactin and growth hormone release in rat pituitary. Endocrinology 1988;123:1128-39
13. Ben-Jonathan N, Chen S, Dunckley JA, et al. Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs. Endocrinology 2009;150:795-802
14. Brooks CL. Molecular mechanisms of prolactin and its receptor. Endocr Rev 2012;33:504-25
15. Nicoll CS, Mayer GL, Russell SM. Structural features of prolactins and growth hormones that can be related to their biological properties. Endocr Rev 1986;7:169-203
16. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: Actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19:225-68
17. Perks CM, Keith AJ, Goodhew KL, et al. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004;91:305-11
18. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27
19. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: Pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204
20. Haga Y, Iwanaga Y, Matsumura F, et al. Curatively resected primary malignant melanoma of the esophagus: Report of a case. Surg Today 1993;23:820-4
21. Bushe CJ, Bradley AJ, Wildgust HJ, et al. Schizophrenia and breast cancer incidence: A systematic review of clinical studies. Schizophr Res 2009;114:6-16
22. Dekkers OM, Romijn JA, de Boer A, et al. The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 2010;13:195-8
23. Peuskens J, Sienaert P, De Hert M. Sexual dysfunction: The unspoken side effect of antipsychotics. Eur Psychiatry 1998(13):23s-30s
24. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004;161:1324-33
25. Shibli-Rahhal A, Schlechte J. The effects of hyperprolactinemia on bone and fat. Pituitary 2009;12:96-104
26. Asai-Sato M, Okamoto M, Endo M, et al. Hypoadiponectinemia in lean lactating women: Prolactin inhibits adiponectin secretion from human adipocytes. Endocr J 2006;53:555-62
27. Frih H, Sahraoui L, Frih N, et al. Facteurs prédictifs de la survenue du stress post-traumatique chez des individus ayant vécu deux évenements de vie majeurs (tremblement de terre et terrorisme en Algérie): Réponse corticotrope et prolactinique a une faible dose de dexaméthasone (0.50 mg). L'É volution Psychiatrique 2009;74:581-91
28. Olff M, Guzelcan Y, de Vries GJ, et al. HPA- and HPT-axis alterations in chronic posttraumatic stress disorder. Psychoneuroendocrinology 2006;31:1220-30
29. Sobrinho LG. Prolactin, psychological stress and environment in humans: Adaptation and maladaptation. Pituitary 2003;6:35-9
30. Pariante CM, Dazzan P, Danese A, et al. Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology 2005;30:1923-31
31. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: Rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004;29:833-46
32. Schlechte J, Dolan K, Sherman B, et al. The natural history of untreated hyperprolactinemia: A prospective analysis. J Clin Endocrinol Metab 1989;68:412-18
33. Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: A review. J Sex Marital Ther 2012;38:281-301
34. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1978-81
35. Harvey PW, Everett DJ, Springall CJ. Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: Role in breast and prostate cancer. Hum Exp Toxicol 2006;25:395-404
36. Murthy S, Wylie KR. Sexual problems in patients on antipsychotic medication. Sex Relationship Ther 2007;22:97-107
37. Voicu VA, de Leon J, Medvedovici AV, et al. New insights on the consequences of biotransformation processes on the distribution and pharmacodynamic profiles of some neuropsychotropic drugs. Eur Neuropsychopharmacol 2012;22:319-29
38. Friberg LE, Vermeulen AM, Petersson KJ, et al. An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment. Clin Pharmacol Ther 2009;85:409-17
39. Miyamoto S, Miyake N, Jarskog LF, et al. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012;17:1206-27
40. Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93
41. Malik P, Kemmler G, Hummer M, et al. Sexual dysfunction in first-episode schizophrenia patients: Results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol 2011;31:274-80
42. Roke Y, van Harten PN, Boot AM, et al. Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 2009;19:403-14
43. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs 2007;21:911-36
44. Anderson GM, Scahill L, McCracken JT, et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61:545-50
45. Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 2003;64:1362-9
46. Schlosser R, Grunder G, Anghelescu I, et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002;46:33-40
47. Fitzgerald P, Dinan TG. Prolactin and dopamine: What is the connection? A review article. J Psychopharmacol 2008;22:12-19
48. Voicu VA, Medvedovici AV, Miron DS, et al. A novel approach on pharmacokinetic/pharmacodynamic correlations of risperidone: Understanding its safety and efficacy profiles. Acta Endocrinologica (Buc)2010;6:265-85
49. Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: Comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006;31:1854-63
50. van de Waterbeemd H, Smith DA, Beaumont K, et al. Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem 2001;44:1313-33
51. van de Waterbeemd H, Smith DA, Jones BC. Lipophilicity in PK design: Methyl, ethyl, futile. J Comput Aided Mol Des 2001;15:273-86
52. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl)2008;197:229-35
53. Olsen CK, Brennum LT, Kreilgaard M. Using pharmacokineticpharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol 2008;584:318-27
54. Zhang L, Zhu H, Oprea TI, et al. QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm Res 2008;25:1902-14
55. Kelder J, Grootenhuis PJ, Bayada D, et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999;16:1514-19
56. Sunderland T, Cohen BM. Blood to brain distribution of neuroleptics. Psychiatry Res 1987;20:299-305
57. Champion MC, Hartnett M, Yen M. Domperidone, a new dopamine antagonist. CMAJ 1986;135:457-61
58. Friedman G. The GI drug column. Subcommittee on FDA related matters, American College of Gastroenterology. Am J Gastroenterol 1983;78:47-8
59. Reddymasu SC, Soykan I, McCallum RW. Domperidone: Review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol 2007;102:2036-45
60. Pardridge WM. Brain drug development and brain drug targeting. Pharm Res 2007;24:1729-32
61. Seeman P. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 2005;162:1984-5
62. Wetzel H, Wiesner J, Hiemke C, et al. Acute antagonism of dopamine D2-like receptors by amisulpride: Effects on hormone secretion in healthy volunteers. J Psychiatr Res 1994;28:461-73
63. Duval F, Guillon MS, Mokrani MC, et al. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder. Psychoneuroendocrinology 2008;33:255-9
64. Paulzen M, Grunder G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol 2007;10:149-51
65. Kirschbaum KM, Henken S, Hiemke C, et al. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res 2008;188:298-303
66. El Ela AA, Hartter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 2004;56:967-75
67. Schmitt U, Kirschbaum KM, Poller B, et al. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav 2012;102:312-20
68. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005;33:165-74
69. Kirschbaum KM, Uhr M, Holthoewer D, et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010;59:474-9
70. Schmitt U, Abou El-Ela A, Guo LJ, et al. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). J Neural Transm 2006;113:787-801
71. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 2010;125(1):169-79
72. Psychoactive Drug Screening Program. Available from: Pdsp.med.unc.edu/ indexR.html [Last accessed 4 January 2013]
73. Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008;69:32-44
74. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123-34
75. Maguire GA. Prolactin elevation with antipsychotic medications: Mechanisms of action and clinical consequences. J Clin Psychiatry 2002;63:56-62
76. Tenback DE, van Harten PN, Slooff CJ, et al. Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances. Neuropsychopharmacology 2006;31:1832-7
77. Aisenberg AC. Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 1995;13:2656-75
78. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994;51:643-50
79. Voicu V, Radulescu FS, Medvedovici A. Toxicological considerations of acetylcholinesterase reactivators. Expert Opin Drug Metab Toxicol 2013;9:31-50
80. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: The role of "switching" medications. J Clin Psychiatry 2007;68:14-23
81. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10:1917-28
82. McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study. J Clin Psychiatry 2013;74(2):170-9
83. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial. Am J Psychiatry 2007;164:1404-10
84. Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007;3:929-51
85. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005;162:1542-3
86. Basterreche N, Zumarraga M, Arrue A, et al. Aripiprazole reverses Paliperidone induced hyperprolactinemia. Actas Esp Psiquiatr 2012;40:290-2
87. Mir A, Shivakumar K, Williamson RJ, et al. Change in sexual dysfunction with aripiprazole: A switching or add-on study. J Psychopharmacol 2008;22:244-53
88. Miller KK. Management of hyperprolactinemia in patients receiving antipsychotics. CNS Spectr 2004;9:28-32
89. Hoffer ZS, Roth RL, Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorigenic hyperprolactinemia. Psychosomatics 2009;50:317-24
90. dos Santos Nunes V, El Dib R, Boguszewski CL, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: A systematic review of randomized controlled trials and meta-analysis. Pituitary 2011;14:259-65
91. Wang AT, Mullan RJ, Lane MA, et al. Treatment of hyperprolactinemia: A systematic review and meta-analysis. Syst Rev 2012; published online 24 July 2012; doi:10.1186/2046-4053-1-33
92. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10:138-51
93. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77
94. Byerly M, Nakonezny P. A pilot study to determine a prolactin threshold that identifies improved sexual functioning when switching from a prolactin-elevating to a prolactin-neutral antipsychotic. Clin Schizophrenia Related Psychoses 2010;3:209-16
95. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:771-91
96. Ramaswamy S, Vijay D, William M, et al. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004;19:45-8
97. DeQuardo Jr. Worsened agitation with aripiprazole: Adverse effect of dopamine partial agonism? J Clin Psychiatry 2004;65:132-3
98. Chiu YH, Chen CH, Lu ML. Worsening psychosis after adding aripiprazole to clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:291-2
99. Thone J. Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole. J Neuropsychiatry Clin Neurosci 2007;19:481-2
100. Kodama M, Hamamura T. Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting. Int J Neuropsychopharmacol 2010;13:549-51
101. Tadori Y, Forbes RA, McQuade RD, et al. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol 2009;607:35-40
102. Steiner W, Laporta M, Chouinard G. Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. Acta Psychiatr Scand 1990;81:437-40
103. Cousins DA, Young AH. Partial agonists in schizophrenia. Br J Psychiatry 2005;186:354
104. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302:1129-34
105. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80:1050-7
106. Molitch ME. Drugs and prolactin. Pituitary 2008;11:209-18
107. Kishimoto T, De Hert M, Carlson HE, et al. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012;25:415-29
108. Rehm S, Stanislaus DJ, Williams AM. Estrous cycle-dependent histology and review of sex steroid receptor expression in dog reproductive tissues and mammary gland and associated hormone levels. Birth Defects Res B Dev Reprod Toxicol 2007;80:233-45